1 The role of exercise in limiting progression from liver inflammation and fibrosis to cirrhosis and carcinoma: a systematic review with meta-analysis of human and animal 2 3 studies Stanhope, E.N.,<sup>1,2</sup> Drummond, A.E.,<sup>3</sup> Swain, C.T.V.,<sup>3,4</sup> Teoh, N.,<sup>5</sup> Farrell, G.,<sup>5</sup> Vallance, J.K.,<sup>6</sup> 4 Lahart, I.M.,<sup>2\*</sup> Lynch, B.M.<sup>3,7\*</sup> 5 6 7 **Institutions** 1. School of Health, Science and Wellbeing, Staffordshire University, United Kingdom. 8 9 2. Faculty of Education, Health and Wellbeing, University of Wolverhampton, United Kingdom. 10 11 3. Cancer Epidemiology Division, Cancer Council Victoria, Melbourne, Australia. 4. Department of Physiotherapy, Melbourne School of Health Sciences, The University of 12 Melbourne, Australia. 13 5. Gastroenterology and Hepatology Unit, The Canberra Hospital and The Australian 14 National University, Canberra, Australia. 15 16 6. Faculty of Health Disciplines, Athabasca University, Athabasca, Canada. 7. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global 17 Health, The University of Melbourne, Carlton, Australia. 18 \* joint senior authors 19 20 **Corresponding author** 21 22 Edward N. Stanhope. School of Health, Science and Wellbeing, Staffordshire University, United 23 Kingdom. edward.stanhope@staffs.ac.uk 24 Abstract 25 26 Background: Exercise may prevent the progression of liver disease and protect against liver cancer. This review with meta-analysis synthesised the evidence from both human and animal 27 studies to better understand whether exercise has the capacity to (i) promote regression of early 28 29 fibrosis; (ii) decrease and/or delay progression to cirrhosis; and (iii) progression to carcinoma.

30

31	Methods: A systematic search was performed to identify studies comprising of humans and
32	animals with liver disease that compared exercise to an inactive or less active control. Outcomes
33	included liver disease regression and progression, and markers of liver function and damage.
34	
35	Results: We found 18 human and 29 animal studies. A single study provided direct evidence that
36	exercise can reverse NAFLD and decrease progression to cirrhosis. Meta-analysis of human
37	studies identified decreases in liver enzymes; ALT (SMD = -0.28, 95%CI = -0.53, -0.03), AST
38	(SMD = -0.12, 95%CI = -0.32, 0.07), GGT (SMD = -0.23, 95%CI = -0.36, -0.10), as well as a
39	small increase in ALP (SMD = $0.23$ , $95\%$ CI = $-0.13$ , $0.59$ ), and liver triglycerides (SMD = $-0.24$ ,
40	95%CI = -0.66, 0.18). Meta-analysis of animal studies identified decreases in liver enzymes;
41	ALT (SMD = -2.85, 95%CI = -4.55, -1.14), AST (SMD = -2.85, 95%CI = -4.55, -1.14), and liver
42	triglycerides (SMD = $-1.36$ , 95% CI = $-2.08$ , $-0.65$ ), liver weight (SMD = $-1.94$ , 95% CI = $-2.78$ , $-2.7$
43	1.10), and the NAFLD activity score (SMD = $-1.36$ , $95\%$ CI = $-2.08$ , $-0.65$ ).
44	
45	Conclusion: Only one study provided direct evidence that exercise has the capacity to regress
46	early fibrosis, as well as delay the progression to cirrhosis. Several studies, however, indicate
47	that exercise intervention reduce markers of liver function and damage.
48	
49	Key words

50 NAFLD, NASH, HCC, HBV, HCV, Physical activity

# 51 Introduction

52 Liver disease is a growing concern worldwide with rising incidence rates irrespective of age, sex, 53 region, or ethnicity (1). The global prevalence of non-alcoholic fatty liver disease (NAFLD) has 54 been estimated to be between 20% and 30% in adults (2), of which ~20% have non-alcoholic 55 steatohepatitis (NASH) (3). The term NAFLD encompasses a continuum of liver pathologies, ranging from non-alcoholic fatty liver (NAFL) to cirrhosis and hepatocellular carcinoma (HCC) 56 57 (4). Simple steatosis with minimal inflammation (NAFL) is relatively benign and has a much 58 lower risk of disease progression than patients with active inflammation (NASH) (5,6). 59 However, once liver fibrosis is present the risk of disease progression and liver-related 60 complications increases dramatically (7) and the chance of developing HCC is seven times 61 greater than that of patients without liver disease (8).

62 According to the World Health Organisation (WHO, 2020), the progression from acute hepatitis 63 B virus (HBV) to chronic HBV is relatively rare, affecting less than 5% of cases. People with 64 chronic HBV infection, however, face a notable lifetime risk of developing cirrhosis or liver 65 cancer (15% to 40%) (9). Conversely, the transition from acute hepatitis C virus (HCV) to 66 chronic HCV is more common. This transition is observed in 55% to 85% of people with HCV, 67 with approximately 15% to 30% of these people progressing to cirrhosis. In both the case of HBV and HCV, the prognosis for people who develop liver cirrhosis or HCC is considerably 68 worse (10–12). Given that HCC is the third leading cause of cancer-related deaths worldwide 69 70 (12), and approximately 90-95% of people with HCC have underlying liver cirrhosis (13), the 71 progression from liver cirrhosis to HCC is a matter of great concern.

The liver is one of only a few organs that can regenerate. Its regeneration capacity, however, isfinite. If there is insufficient availability of hepatocytes, liver disease can become irreversible

with severe consequences, such as increased sensitivity to noxious substances (encephalopathy),
increased risk of gastrointestinal (GI) bleeding (varices and coagulopathy), and decreased bile
flow (14).

77 Lifestyle modification, such as increasing physical activity, may help improve liver disease 78 outcomes. Emerging evidence suggests that increasing physical activity may enhance liver 79 repair, reduce the risk of liver diseases, such as NAFLD and liver cancer, and slow the 80 progression from HBV, HCV, NAFLD, and alcohol-related liver disease to liver cirrhosis and 81 HCC (11,12). Whereas the epidemiological evidence suggests a protective effect of increased 82 physical activity against liver cancer, the experimental evidence remains inconclusive—largely 83 due to factors such as heterogeneity in the assessment of 'exposure'—which limits support for 84 exercise intervention in treating liver disease (15).

85 Examining the evidence for the biological plausibility of exercise reducing the risk of liver disease can provide support for causal inference. Preclinical studies indicate that, if hepatic 86 87 steatosis can be reversed through exercise intervention, then liver inflammation and fibrosis can 88 be resolved (4). Due to the invasive nature of liver biopsy, much of the mechanistic evidence for 89 the effects of exercise on liver disease comes from animal studies. However, in vivo animal 90 studies suggest liver fibrosis is more susceptible to regeneration in animals compared to humans 91 (16), and therefore species-specific liver regeneration differences cannot be ruled out (17). Hence, to ensure translation, human mechanistic studies must also be examined. 92

Developing a better understanding of how exercise affects intermediate biological processes may
provide insight into the best ways to alter exposures for disease prevention. The overarching
objective of this review is to improve the understanding of whether exercise has the capacity to

96 (i) promote regression of early fibrosis, (ii) decrease or delay progression to cirrhosis; and (iii)

- 97 progression to carcinoma.
- 98 Methodology
- 99 Study Design
- 100 This was a systematic review and meta-analysis of human and animal studies.

101

### **102** Search Strategy

Relevant publications were identified using tailored search strategies of MEDLINE (via Ovid)
from 1946 - June 27, 2021, EMBASE (via Ovid) from 1974 - June 27, 2021, and SportDiscus
(via EBSCO) from 1985 - July 4, 2021. The tailored search strategies used a combination of
medical subject headings and free text terms. A version of the search strategy for MEDLINE is
presented in Appendix 1. Searches were performed on June 29, 2020, and updated on July 22,
2021.

109

### 110 Eligibility criteria

111 Both human and animal studies published in peer-reviewed journals were eligible for inclusion.

112 Only studies published in English were included. Conference abstracts were excluded.

113

We included human studies with parallel group randomized controlled trials (RCTs) and randomized crossover trials (RXTs) designs, whereas non-randomized interventions and observational studies were excluded due to their lower level of evidence for establishing causal effects. Participants included adults (>18 years old) with liver inflammation (including NAFL and NASH) or fibrosis. Populations with other clinically relevant health conditions (e.g.,

119 metabolic syndrome, type II diabetes) were also considered. Acceptable interventions included 120 any exercise intervention that disturbed the bodies homeostasis through muscular activity, 121 whether exclusively concentric, eccentric, or isometric, or a combination thereof (18). We 122 considered studies that offered general dietary recommendations in addition to exercise but 123 excluded studies that combined exercise and dietary interventions (e.g., caloric restriction). We excluded studies if the effects of exercise could not be isolated and if the period of exercise was 124 125 less than seven days. We included studies that contained at least one control arm that did not 126 receive exercise.

127

Regarding animal studies, we included parallel randomized controlled trials involving genetic 128 129 and induced models of liver disease; induction methods included, but were not limited to, 130 exposure to diet and alcohol. We excluded single-group pre-post intervention studies and those 131 lacking a non-exercise period for NAFLD induction or a non-exercise induction period which 132 lasted less than eight weeks, as it is improbable to induce NAFLD within such a short timeframe 133 (19,20). Eligible interventions included any form of exercise as defined by Winter & Fowler 134 (2009). We excluded studies if the effects of exercise could not be isolated (e.g., exercise and caloric restriction). To be considered for inclusion, the period of exercise intervention must have 135 136 been greater than seven days and studies were required to have at least one control group that did 137 not receive exercise.

138

We included studies that used invasive or non-invasive procedures to determine whether i)
inflammation or fibrosis had reverted to an earlier stage of the disease or resolved; (ii)
progressed to cirrhosis; (iii) and/or progressed to carcinoma.

142

143 The gold standard for evaluating liver fibrosis, cirrhosis, and carcinoma (cancer) is a liver biopsy, whereby a small tissue sample from the liver is extracted for microscopic examination. 144 145 enabling the assessment of fibrosis (scarring), cirrhosis (advanced scarring), and the presence of 146 carcinoma or cancerous cells. However, liver biopsy is an invasive procedure that may have 147 some risks associated with it, such as bleeding or infection. As a result, non-invasive methods, 148 including FibroScan (Transient Elastography), blood tests, magnetic resonance elastography 149 (MSE), shear wave elastography (SWE), fibrosis blood panels and other imaging modalities (i.e., 150 CT and MRI) have been developed and were included in our review.

151

### **152** Selection of studies

153 Study eligibility was judged against the pre-defined inclusion and exclusion criteria. Two authors 154 (ES, IML) independently screened the titles and abstracts of articles for eligibility. In cases of 155 disagreement the two authors discussed each case and tried to reach a consensus. If a consensus 156 could not be reached a third reviewer was consulted (BL). If inadequate information was 157 available in the title and abstract to determine eligibility it was included for next stage (full text) 158 review. The same two authors (ES, IML) independently reviewed the full text of articles that 159 were included based on the title and abstract screening. In cases where there was disagreement 160 about the eligibility of an article, the two authors aimed to reach a consensus. If a consensus 161 could not be reached a third reviewer (BL) was consulted. The authors were not blind to study 162 authors, journals, or results. A screening log was maintained and the number of excluded studies 163 and their reason for exclusion recorded.

## 165 **Data extraction**

Data extraction for human studies was performed by ES and IML using a pre-piloted system, 166 whereby one author extracted data into a table, and another validated the data extraction. Data 167 168 extraction for animal studies was performed in the same way by BL and AD. Extracted data 169 included study details (e.g., authors, year), study design, population (e.g., sample size, 170 demographic information, health status), intervention details (e.g., duration, exercise frequency, 171 intensity, time, type), comparator conditions, outcome details (e.g., definition, assessment 172 method), and statistical measures (e.g., post-intervention means and standard deviation). The 173 Webplot digitiser was used to extract data from studies that exclusively presented their results in graphical form. 174

175

### 176 Data synthesis and meta-analysis

177 Extracted data were summarised and presented descriptively. For outcomes that were 178 consistently defined and reported in at least three studies, random effects meta-analysis was used 179 to estimate the effects of exercise on liver outcomes. Meta-analysis compared post-intervention 180 means and standard deviation between intervention and control groups. When studies had more 181 than one intervention group that met the criteria for inclusion, post-intervention means and 182 standard deviations were combined as per the Cochrane Collaboration manual (21). Meta-183 analysis effect estimates are presented as standardised mean difference (SMD) and 95% confidence interval (95%CI). Heterogeneity was assessed using the  $I^2$  statistic. Publication bias 184 185 was assessed via visual inspection of funnel plots. For animal studies, meta-regression was used 186 to assess the influence of study year, study location (i.e., region), animal type, disease, and 187 disease inducement method on effect estimates. For human studies, meta-regression was used to

188	assess the influence of study year, study region, and disease type on effect estimates. Results of
189	studies not included in the meta-analyses were presented descriptively. All statistical analyses
190	were performed using Stata version 16 (Stata Corporation, College Station, Texas).

191

192 **Results** 

### **193** Identification of studies

Search results are presented in Figure 1. Of the 1,535 records identified via database search,
1,352 titles and abstracts were screened, and 174 full texts were assessed for eligibility, with 60
full texts meeting all criteria for inclusion. Of these, there were 29 interventions in animals and
18 interventions conducted in humans.

198

### **199** Study characteristics

200 Study characteristics of human studies are presented in Table 1. Studies were conducted in Asia 201 (animal = 6, human = 4), Australia (human = 1), Europe (animal = 8, human = 6), the Middle 202 East (animal = 3, human = 3), North America (animal = 9, human = 1), or South America 203 (animal = 4, human = 1). A total of 1,976 participants with a median (IQR) sample of 47 (27– 204 135). There was a slightly higher proportion of male compared to female participants across 205 studies (median % = 52% vs. 48%); two studies included only female participants (22,23). The 206 median (IQR) average age was 53 (49–55) years and median (IQR) average BMI was 32 (30–33)  $kg/m^2$ . 207

- 209 The type of liver disease studied included NAFLD (animal = 17, human = 14), NASH (animal =
- 210 5, human = 1), hepatic steatosis (animal = 4), liver cirrhosis (human = 1), liver fibrosis (animal = 4)

211 1), polycystic liver disease (animal = 1), metabolic syndrome (human = 1), type II diabetes
212 (human = 1), and extrahepatic obstruction (animal = 1).

213

214 All but one (24) of the human studies provided details on how NAFLD was diagnosed. NAFLD 215 diagnosis methods in human studies included: proton magnetic resonance spectroscopy (MRS) 216 alone (25–27), ultrasonography alone (22), MRS and ultrasonography (28), ultrasonography and 217 elevated alanine aminotransferase (ALT) (29), Asia Pacific Working Party guidelines (30,31), 218 liver biopsy (23), and controlled attenuation parameter (CAP) measurements performed via 219 vibration-controlled elastography (VCTE) (32). Liver biopsies were used to diagnose NASH in 220 the only study that consisted of patients diagnosed with this condition (33). Whereas, in one 221 study (34) a variety of measures were used to diagnose liver cirrhosis (computed tomography, 222 MRI, transient elastography, or liver biopsy).

223

224 Human studies had one (N = 13), two (N = 4), or three (N = 1) intervention arms that were 225 relevant to this review. The interventions included only moderate-intensity continuous training 226 (N = 8), resistance training (N = 4), high-intensity interval training (N = 2), moderate-intensity 227 continuous training combined with resistance training (N = 4), vigorous-intensity training (N = 4)228 1), or physical activity guidelines and counselling support (N = 1). The comparison conditions included a no intervention control (N = 7), standard care (N = 3), general diet and/or physical 229 230 activity advice (N = 3), a wait-list control (N = 1), placebo supplement (N = 1), control diet (N = 1)231 1), or stretching (N = 1).

Study characteristics of animal studies are presented in Table 2. Animal studies included an
approximate total of 992 animals and had a median [inter-quartile range (IQR)] of 32 (24–39),
although it was not possible to discern the exact number due to study reporting quality (e.g., a
study may have reported '7–8' mice per group). There were 17 studies with rats and 12 studies
with mice.

238

In animal studies, these diseases were induced via diet (N = 22), genetic phenotype (N = 6), or drug induced (N = 1). Animal studies had either one (N = 17) or two (N = 12) intervention arms relevant to this review. Interventions in animal studies included continuous exercise (e.g., treadmill running, N = 24), voluntary exercise (e.g., voluntary wheel running, N = 8), or swimming (N = 5).

244

Only one study (human = 1) directly reported the number of NAFLD participants who experienced disease regression, reduction, or progression. In most studies, liver function and/or damage were used as surrogate markers for remission and progression, and included tests for liver enzymes: alanine transaminase (ALT) (animal = 18, human = 16), aspartate transaminase (AST) (animal = 11, human = 15), alkaline phosphatase (ALP) (animal = 2, human = 4), and gamma-glutamyl transferase (GGT) (animal = 1, human = 12).

251

The assessment of liver triglyceride content included hepatic triglyceride content (HTGC)
(animal = 9), intrahepatic triglyceride content (IHTG) (human = 1), HTGC/IHTG (human = 5),
liver fat percentage (human = 3), intra-hepatocellular lipid (IHCL) (human = 1), liver lipid

percentage (animal = 1), intrahepatic lipid content (IHL) (human = 4), liver triacylglycerol
(TAG) (animal = 5), and hepatic fat content (HFC) (human = 1).

257

For the evaluation of liver steatosis and related measures, the fatty liver index (human = 1), ferritin (human = 4), fetuin A (human = 1), hepatic steatosis (human = 2), NAFLD (nonalcoholic fatty liver disease) (human = 1), NAFLD activity score (NAS) (animal = 5), fibrosis score (animal = 1, human = 2), and steatosis score (animal = 3) were included.

262

Additionally, other liver outcome measures were taken into account, such as liver droplet size (animal = 4), liver stiffness (human = 2), spleen stiffness (human = 1), liver diacylglycerol (DAG) (animal = 3), hepatorenal index (HRI) (human = 1), liver platelets (PLT) (human = 1), hepatic tuberculosis (TB) (human = 1), liver weight (animal = 6), and vascular endothelial growth factor (VEGF) (human = 1).

268

### 269 Liver disease regression and/or progression

270 In our review, only one study (25) directly investigated the impact of exercise on the remission 271 or progression of NAFLD. The findings revealed that 14% (n = 3/22) of participants assigned to 272 the exercise group achieved a decrease in hepatic fat content (HFC) to less than 5.6% (normal 273 levels), while this was observed in only 11% (n = 2/18) of those who received no intervention. 274 Moreover, 54% (n = 12/22) of the exercise group experienced a reduction in HFC, while only 275 17% (n = 3/18) in the no intervention group showed a similar improvement. Furthermore, 276 elevated HFC was observed in only 32% (n = 7/22) of participants in the exercise group, compared to 72% (n = 13/18) in the no intervention arm. These findings suggest a positive 277

association between exercise intervention and the regression of early fibrosis, as well as a delay
in the progression to cirrhosis. We found no studies that directly evaluated the progression to
HCC.

281

## 282 Markers of liver function and damage

283 Meta-analysis of human studies was possible for outcomes ALT, AST, ALP, GGT, and hepatic 284 triglyceride content only (Figure 2). Meta-analysis of animal studies was possible for outcomes 285 ALT, AST, NAS, and liver triglycerides only (Figure 3). We conducted separate meta-regression analyses for human (Supplementary Table 1) and animal studies (Supplementary Table 2). In 286 287 human studies, we accounted for year, region, disease, and study type. Meanwhile, in animal 288 studies, we controlled for year, region, animal type, disease, and inducement. Results of meta-289 regression and funnel plots are presented in supplementary material. Results of individual studies 290 not included in the meta-analyses are presented in supplementary table 3 and 4.

291

### 292 Liver enzymes

293 Meta-analysis of studies that assessed the effects of exercise on ALT are presented in Figure 2A 294 (human studies) and Figure 3A (animal studies). In the human studies, participants who were 295 assigned to the exercise group exhibited a modest reduction in ALT levels compared to those in 296 the control group (Studies = 12, N = 1,209, SMD = -0.28, 95%CI = -0.53, -0.03). Moreover, in 297 animal studies, a greater difference in ALT levels was observed between the exercise and control 298 groups (Studies = 15, N = 274, SMD = -2.61, 95%CI = -3.91, -1.30). Heterogeneity was considerable in animal studies ( $I^2 = 94\%$ ) and substantial in human studies ( $I^2 = 65\%$ ). Some of 299 300 the heterogeneity in the animal studies could be explained by animal type, with higher effect

suggested likely publication bias in animal studies but not for human studies (Supplementary
Figure 1). Additional individual studies not included in the meta-analysis reported either a
statistically significant reduction in ALT following intervention compared to the control group
(35) or no statistically significant difference (28,36) (Supplementary Table 3).

306

307 Meta-analysis of studies that assessed the effects of exercise on AST are presented in Figure 2B 308 (human studies) and Figure 3B (animal studies). Participants assigned to the intervention showed 309 a slight difference in AST compared to the control group, favouring the intervention (Studies = 310 10, N = 1,148, SMD = -0.12, 95%CI = -0.32 to 0.07). However, the certainty of this finding was 311 limited by confidence intervals that crossed the null. Additionally, animals assigned to the 312 exercise intervention demonstrated a significant difference in AST compared to the control group 313 (Studies = 8, N = 146, SMD = -2.88, 95% CI = -4.78 to -0.98). Heterogeneity was considerable in animal studies ( $I^2 = 95\%$ ) and moderate in human studies ( $I^2 = 39\%$ ). Funnel plots suggested 314 315 likely publication bias in animal studies but not in human studies. Meta-regression results are 316 presented for human (Supplementary Table 1) and animal studies (Supplementary Table 2) in the 317 supplementary materials. Some of the heterogeneity in the human and animal studies meta-318 analysis was explained by study region. Furthermore, in the animal studies, study year explained 319 some of the heterogeneity in the meta-analysis. Individual studies that were not included in the 320 meta-analysis identified a statistically significant reduction in AST in the intervention compared 321 to control arm following intervention (35) or no statistically significant difference (28,36) 322 (Supplementary Table 3).

324 Meta-analysis of human studies that assessed the effects of exercise on ALP are presented in 325 Figure 2C. Despite the confidence intervals crossing the null, our analysis revealed a small increase in ALP among those assigned to exercise when compared with the control group 326 327 (Studies = 3, N = 130, SMD = 0.23, 95% CI = -0.13, 0.59). There was no evidence of 328 heterogeneity ( $I^2 = 0\%$ ), nor was there evidence of publication bias. Meta-regression was not 329 possible for ALP in either human or animal studies. Two individual animal studies examined the 330 effects of exercise on ALP, both found a decreases in ALP for exercise compared to control 331 (37,38) (Supplementary Table 4).

332

333 Meta-analysis of human studies that assessed the effects of exercise on GGT are presented in 334 Figure 2D. There was a small decrease in GGT in participants receiving exercise intervention 335 compared to controls (Studies = 10, N = 1,142, SMD = -0.23, 95%CI = -0.36, -0.10). Heterogeneity was low  $(I^2 = 6\%)$  and there was no clear evidence of publication bias 336 337 (Supplementary Figure 1). There were no statistically significant findings from the meta-338 regression (Supplementary Table 1). In three individual studies not included in the meta-analysis, 339 two (35,36) identified decreases in GGT following exercise relative to control (Supplementary 340 table 3). One study (28) did not identify definitive differences between exercise and control groups. There was no difference in GGT between groups in one animal study (39) 341 342 (Supplementary Table 4).

343

344

345 Liver triglyceride content

346 Meta-analysis of human studies that assessed the effects of exercise on HTGC are presented in 347 Figure 2E. Participants assigned to exercise showed, on average, HTGC compared to the control group (Studies = 3, N = 101, SMD = -0.24, 95% CI = -0.66, 0.18). However, it's worth noting 348 that the confidence intervals overlapped the null value. Heterogeneity was low  $(I^2 = 0\%)$  and 349 350 there was no clear evidence of publication bias (Supplementary Figure 1). Meta-regression was 351 not possible for HTGC in human studies. The percentage decrease in HTGC was greater 352 following moderate and high intensity exercise compared to control in one individual human 353 study not included in the meta-analysis (28). There was no difference between moderate and 354 high intensity exercise.

355

356 Meta-analysis of animal studies that assessed the effects of exercise on liver triglycerides are 357 presented in Figure 3D. There was a large difference in liver triglycerides between exercise and 358 control groups (Studies = 10, N = 172, SMD = -1.94, 95%CI = -3.87, 0.00). Heterogeneity was, however, considerable ( $I^2 = 96\%$ ) and there was evidence of publication bias (Supplementary 359 360 Figure 2). Meta-regression indicated that some of the heterogeneity could be explained by animal 361 type-with larger effect estimates observed for studies that used rats-but not by year, region, 362 disease, or inducement (Supplementary Table 2). Individual animal studies not included in the 363 meta-analysis suggested lower liver triglycerides for exercise compared to control (40).

364

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), individual studies suggested that exercise can decrease liver TAG (41–43), HFC (25), the fatty liver index (44), IHCL (45), and IHL (24,46).

### 369 Liver steatosis and related measures

Meta-analysis of all four animal studies that assessed the effects of exercise on NAS are presented in Figure 3C. There was a large decrease in NAS with exercise versus control (Studies = 4, N = 98, SMD = -1.36, 95%CI = -2.08, -0.65). Heterogeneity was substantial (I<sup>2</sup> = 59%) and there was some evidence of publication bias (Supplementary Figure 2). Meta-regression of NAS was not possible and therefore, the heterogeneity observed remained unexplained.

375

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), the findings on Ferritin were mixed in the literature; two studies (35,36) reported a decrease with exercise compared to controls, while two other studies (23,31) found no statistically significant difference. Similarly, one study (47) observed differences in fibrosis score between exercise and control groups, while another (33) did not find any distinction.

381

### 382 Other relevant liver outcome measures

Meta-analysis of all six animal studies that assessed the effects of exercise on liver weight are presented in Figure 3E. There was a large difference in liver weight between exercise and control groups (Studies = 6, N = 144, SMD = -1.94, 95%CI = -2.78, -1.10). Heterogeneity was considerable (I<sup>2</sup> = 77%), although could not clearly be explained by factors included in the metaregression analysis (Supplementary Table 2). There was possible publication bias evident in the funnel plots (Supplementary Figure 2).

For outcomes not included in the meta-analysis (Supplementary Table 3 and Table 4), individual
studies suggested that exercise can decrease liver DAG (42,48), hepatic stiffness (31) and HRI

392 (36). There were null findings for liver stiffness (34), spleen stiffness (34), and VEGF (23).

### 393 Discussion

This current review synthesized the evidence for the effect of exercise interventions versus control/standard care on liver function and disease in people and animals with established liver disease. Only one study directly reported whether liver disease (NAFLD) regressed or progressed in response to exercise intervention. Most studies included in this review compared measures of liver function and/or damage between exercise and non-exercise interventions. The findings of these studies support the biological plausibility for a protective effect of exercise on liver function and disease.

401 The primary strength of this review is the synthesis of findings from both human and animal studies. While there is a wealth of data from animal studies relevant to human health, systematic 402 403 reviews, which are common practice in clinical and public health research, remain less common 404 in animal research. Animal studies offer a unique advantage in exploring liver outcome measures 405 that are not feasible to obtain through biopsy in humans. However, it is essential to recognize 406 that the responses observed in animals may not always directly translate to human-specific 407 outcomes. On the other hand, human studies heavily rely on surrogate measures of liver function 408 and damage. By incorporating results from both human and animal studies, this review greatly 409 enhances our understanding of the effects of exercise on liver function, as well as the potential 410 translation of animal study findings to human contexts.

This current review also has limitations that should be considered when interpreting the findings. First, we did not perform a risk of bias assessment using a pre-existing risk of bias tool. While tools for assessing study quality in human clinical trials have been modified and applied to animal studies (e.g., SYRCLE), when piloting this tool most animal studies scored poorly simply because the information was not reported.

416 There was substantial to considerable heterogeneity in the meta-analyses, particularly the meta-417 analyses of the animal studies, which may limit confidence in the final effect estimates. Sources 418 of heterogeneity present in animal studies that were not present in the human studies included 419 species (e.g., mouse type, rat type) as well as methods used to induce liver disease (e.g., forced 420 feeding, genetic selection). These are in addition to sources of variation present in human 421 studies, such as variations in study design and methods, participant age and sex, exercise type, 422 dose, or duration, and outcome assessment methods. Owing to the studies identified, this review 423 is limited in its ability to examine differing effects for the type and dose of exercise on liver 424 function and/or damage.

425 Our study's findings indicate that exercise interventions have a positive impact on liver health 426 and function when compared to non-exercise comparison groups. These results align with 427 evidence from epidemiological studies, which have shown that higher levels of physical activity 428 are associated with reduced instances of fatty liver and a decreased risk of liver cancer. For 429 example, in a meta-analysis of observational studies (49), higher (90th percentile) compared to 430 lower (10th percentile) duration of leisure-time physical activity was associated with decreased 431 liver cancer risk (HR = 0.73, 95%CI: 0.55, 0.98). While this epidemiological evidence suggests an association between exercise and outcomes like liver cancer, results from this current review 432

support the biological plausibility of the findings. That is, exercise may reduce the risk of livercirrhosis and/or cancer by reducing measures of liver function and/or damage.

435 Improvement in liver enzymes, liver triglyceride content, and steatosis was evident in both 436 human and animal studies, but the effect estimates were generally larger in the meta-analysis of 437 animal studies compared with the human studies. This may, in part, reflect inter-species 438 differences, with greater potential for liver regeneration in animals. Alternatively, these larger 439 effect estimates may be due to a greater ability to control for sources of variation in animal 440 compared to human studies, who are likely to vary in factors such as intervention adherence, 441 diet, alcohol consumption, body fatness, as well as exercise history and tolerance. Nonetheless, 442 that improvements were present in both humans and animals supports the translation of findings 443 and relevance to people with liver disease.

444 This current review found an effect of exercise on liver outcomes, but it did not attempt to 445 determine whether these are direct or indirect effects. That is, is the benefit of exercise due to the 446 exercise itself or other factors such as fat loss that may follow exercise participation. Findings 447 from individual studies included within the review suggest at least some of the effects of exercise 448 may be via fat loss (28). However, other studies have proposed mechanisms independent of fat 449 loss, such as facilitating change via the effect of exercise on insulin signalling and serum lipid 450 concentrations, which may lead to an increased ability to suppress lipolysis in adipose tissue, 451 resulting in decreased free fatty acid delivery to the liver (47).

The identification of exercise's impact on liver function and damage provides essential support for the idea that exercise might be linked to liver cancer. As liver cancer is a rare form of cancer, directly examining this relationship presents challenges. Nevertheless, it is important to

455 emphasize that this discovery is just one step in the broader research pathway. Conducting
456 further research is necessary to delve into how these measures specifically influence the
457 incidence of liver cirrhosis and/or cancer (HCC).

458

### 459 Conclusion

In conclusion, a single investigation focusing on the effect of exercise on the progression and 460 461 remission of NAFLD revealed a significant association between exercise intervention and the 462 regression of initial fibrosis, as well as a delay in the progression of cirrhosis. Moreover, a comprehensive review of existing literature reveals consistent indications of exercise's positive 463 impact on liver function and reduction of liver damage in both human subjects and animal 464 models with established liver disease. These collective results substantiate the biological 465 466 plausibility of exercise as a beneficial therapeutic strategy for enhancing liver function and 467 combatting liver disease. Nonetheless, further research and clinical trials are warranted to fully 468 elucidate the mechanisms underlying these observed effects and to establish more robust 469 guidelines for exercise-based interventions in liver disease management.

470

### 471 Acknowledgments

All authors were involved in conception and design. A. E. D. performed the literature searches,
with A. E. D. and J. K. V. selecting articles for exclusion and inclusion, with any disagreement
resolved by discussion with B. M. L. Full texts were assessed by E. N. S and I. M. L, with any
disagreement resolved by discussion with B. M. L. Data was extracted from human studies by E.
N. S. and I. M. L, and from animal studies by A. E. D. and B. M. L. Meta-analysis was
conducted by C. T. V. S. All authors contributed to the writing and revision of the manuscript.

478

# 479 **Conflicts of interest**

- 480 The authors declare no competing interests. No funding was received for this work. The results
- 481 of the study are presented clearly, honestly, and without fabrication, falsification, or
- 482 inappropriate data manipulation.

### 483 **References**

- Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of Liver Diseases in the World. J
   Hepatol. 2019 Jan 1;70(1):151–71.
- Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology. 2016;64(1):73–84.
- Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-Analysis of Paired-Biopsy Studies. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015 Apr;13(4):643-654.e1-9; quiz e39-40.
- 493 4. Loomba R, Friedman SL, Shulman GI. Mechanisms and Disease Consequences of
  494 Nonalcoholic Fatty Liver Disease. Cell. 2021 May 13;184(10):2537–64.
- 495 5. Day CP. Natural History of NAFLD: Remarkably Benign in the Absence of Cirrhosis.
  496 Gastroenterology. 2005 Jul;129(1):375–8.
- Younossi ZM, Marchesini G, Pinto-Cortez H, Petta S. Epidemiology of Nonalcoholic Fatty
   Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation.
   Transplantation. 2019 Jan;103(1):22–7.
- Ekstedt M, Franzén LE, Mathiesen UL, Thorelius L, Holmqvist M, Bodemar G, et al. Long Term Follow-up of Patients with NAFLD and Elevated Liver Enzymes. Hepatol Baltim Md.
   2006 Oct;44(4):865–73.
- Mittal S, Sada YH, El-Serag HB, Kanwal F, Duan Z, Temple S, et al. Temporal Trends of Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma in the Veteran Affairs Population. Clin Gastroenterol Hepatol Off Clin Pract J Am Gastroenterol Assoc. 2015 Mar;13(3):594-601.e1.
- Mak LY, Cruz-Ramón V, Chinchilla-López P, Torres HA, LoConte NK, Rice JP, et al. Global
   Epidemiology, Prevention, and Management of Hepatocellular Carcinoma. Am Soc Clin
   Oncol Educ Book. 2018 May 23;(38):262–79.
- 510 10. Czaja AJ. Review Article: The Prevention and Reversal of Hepatic Fibrosis in Autoimmune
   511 Hepatitis. Aliment Pharmacol Ther. 2014 Feb;39(4):385–406.
- 512 11. Sepanlou SG, Safiri S, Bisignano C, Ikuta KS, Merat S, Saberifiroozi M, et al. The Global,
  513 Regional, and National Burden of Cirrhosis by Cause in 195 Countries and Territories,
  514 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017. Lancet
  515 Gastroenterol Hepatol. 2020 Mar;5(3):245–66.
- 516 12. Shiani A, Narayanan S, Pena L, Friedman M. The Role of Diagnosis and Treatment of
  517 Underlying Liver Disease for the Prognosis of Primary Liver Cancer. Cancer Control. 2017
  518 Sep 1;24(3):107327481772924.
- 519 13. Forner A, Llovet JM, Bruix J. Hepatocellular Carcinoma. The Lancet. 2012
  520 Mar;379(9822):1245–55.


- 521 14. Sharma A, Nagalli S. Chronic Liver Disease. In: StatPearls [Internet]. Treasure Island (FL):
- 522 StatPearls Publishing; 2021 [cited 2021 Jun 28]. Available from:
- 523 http://www.ncbi.nlm.nih.gov/books/NBK554597/
- 524 15. WCRF. Diet, Nutrition, Physical Activity and Liver Cancer. 2015;52.
- 525 16. Desmet VJ, Roskams T. Cirrhosis Reversal: A Duel between Dogma and Myth. J Hepatol.
  526 2004 May 1;40(5):860–7.
- 527 17. Cordero-Espinoza L, Huch M. The Balancing Act of the Liver: Tissue Regeneration versus
   528 Fibrosis. J Clin Invest. 2018;128(1):85–96.
- 18. Winter EM, Fowler N. Exercise defined and quantified according to the Système
   International d'Unités. J Sports Sci. 2009 Mar 1;27(5):447–60.
- 531 19. Farrell G, Schattenberg JM, Leclercq I, Yeh MM, Goldin R, Teoh N, et al. Mouse Models of
  532 Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human
  533 Nonalcoholic Steatohepatitis. Hepatol Baltim Md. 2019 May;69(5):2241–57.
- 534 20. Haczeyni F, Yeh MM, Ioannou GN, Leclercq IA, Goldin R, Dan YY, et al. Mouse Models of
  535 Non-Alcoholic Steatohepatitis: A Reflection on Recent Literature. J Gastroenterol Hepatol.
  536 2018 Jul;33(7):1312–20.
- 537 21. Higgins JP, Green S, editors. Cochrane Handbook for Systematic Reviews of Interventions:
  538 Cochrane Book Series [Internet]. 1st ed. Wiley; 2008 [cited 2023 Jul 26]. Available from:
  539 https://onlinelibrary.wiley.com/doi/book/10.1002/9780470712184
- 540 22. Kelardeh B, Rahmati-Ahmadabad S, Farzanegi P, Helalizadeh M, Azarbayjani MA. Effects
  541 of non-linear resistance training and curcumin supplementation on the liver biochemical
  542 markers levels and structure in older women with non-alcoholic fatty liver disease. J Bodyw
  543 Mov Ther. 2020 Jul;24(3):154–60.
- S44 23. Rezende REF, Duarte SMB, Stefano JT, Roschel H, Gualano B, De Sá Pinto AL, et al.
  S45 Randomized clinical trial: benefits of aerobic physical activity for 24 weeks in
  postmenopausal women with nonalcoholic fatty liver disease. Menopause. 2016
  S47 Aug;23(8):876–83.
- 548 24. Hallsworth K, Fattakhova G, Hollingsworth KG, Thoma C, Moore S, Taylor R, et al.
  549 Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease
  550 independent of weight loss. Gut. 2011 Sep 1;60(9):1278–83.
- 551 25. Cheng S, Ge J, Zhao C, Le S, Yang Y, Ke D, et al. Effect of aerobic exercise and diet on
  552 liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized
  553 controlled trial. Sci Rep. 2017 Nov 21;7(1):15952.
- 26. Pugh C, Sprung V, Aarons G, Richardson P, Shojaee-Moradie F, Umpleby A, et al. Exercise
  training reverses endothelial dysfunction in nonalcoholic fatty liver disease. Am J PhysiolHeart Circ Physiol. 2014;307(9):H1298–306.

- 557 27. Sullivan S, Kirk EP, Mittendorfer B, Patterson BW, Klein S. Randomized trial of exercise
  558 effect on intrahepatic triglyceride content and lipid kinetics in nonalcoholic fatty liver disease.
  559 Hepatology. 2012 Jun;55(6):1738–45.
- 28. Zhang HJ, He J, Pan LL, Ma ZM, Han CK, Chen CS, et al. Effects of Moderate and
  Vigorous Exercise on Nonalcoholic Fatty Liver Disease: A Randomized Clinical Trial. JAMA
  Intern Med. 2016 Aug 1;176(8):1074.
- 563 29. Pugh C, Cuthbertson DJ, Sprung VS, Kemp GJ, Richardson P, Margot Umpleby A, et al.
  564 Exercise training improves cutaneous microvascular function in nonalcoholic fatty liver
  565 disease. Am J Physiol-Endocrinol Metab. 2013 Jul 1;305(1):E50–8.
- 30. Abdelbasset WK, Tantawy SA, Kamel DM, Alqahtani BA, Elnegamy TE, Soliman GS, et al.
  Effects of High-Intensity Interval and Moderate-Intensity Continuous Aerobic Exercise on
  Diabetic Obese Patients with Nonalcoholic Fatty Liver Disease: A Comparative Randomized
  Controlled Trial. Medicine (Baltimore). 2020 Mar;99(10):e19471.
- 31. Takahashi A, Abe K, Usami K, Imaizumi H, Hayashi M, Okai K, et al. Simple Resistance
  Exercise helps Patients with Non-alcoholic Fatty Liver Disease. Int J Sports Med. 2015 Jun
  19;36(10):848–52.
- 32. Tutino V, De Nunzio V, Caruso M, Bonfiglio C, Franco I, Mirizzi A, et al. Aerobic Physical
  Activity and a Low Glycemic Diet Reduce the AA/EPA Ratio in Red Blood Cell Membranes
  of Patients with NAFLD. Nutrients. 2018 Sep 13;10(9):1299.
- 33. Houghton D, Thoma C, Hallsworth K, Cassidy S, Hardy T, Burt AD, et al. Exercise Reduces
  Liver Lipids and Visceral Adiposity in Patients With Nonalcoholic Steatohepatitis in a
  Randomized Controlled Trial. Clin Gastroenterol Hepatol. 2017 Jan;15(1):96-102.e3.
- 34. Sirisunhirun P, Bandidniyamanon W, Jrerattakon Y, Muangsomboon K, Pramyothin P,
  Nimanong S, et al. Effect of a 12-week home-based exercise training program on aerobic
  capacity, muscle mass, liver and spleen stiffness, and quality of life in cirrhotic patients: a
  randomized controlled clinical trial. BMC Gastroenterol. 2022 Dec;22(1):66.
- 35. St. George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of
  physical activity in patients with nonalcoholic fatty liver disease. Hepatology. 2009
  Jul;50(1):68–76.
- 36. Zelber-Sagi S. Effect of Resistance Training on Non-Alcoholic Fatty-Liver Disease a
   Randomized-Clinical Trial. World J Gastroenterol. 2014;20(15):4382.
- 37. Marques CMM, Motta VF, Torres TS, Aguila MB, Mandarim-de-Lacerda CA. Beneficial
  effects of exercise training (treadmill) on insulin resistance and nonalcoholic fatty liver
  disease in high-fat fed C57BL/6 mice. Braz J Med Biol Res. 2010 May;43(5):467–75.
- 38. Schultz A, Mendonca LS, Aguila MB, Mandarim-de-Lacerda CA. Swimming training
  beneficial effects in a mice model of nonalcoholic fatty liver disease. Exp Toxicol Pathol.
  2012 May;64(4):273–82.

- 39. Silva RN, Bueno PG, Avó LRS, Nonaka KO, Selistre-Araújo HS, Leal AMO. Effect of
  physical training on liver expression of activin A and follistatin in a nonalcoholic fatty liver
  disease model in rats. Braz J Med Biol Res. 2014 Jul 25;47(9):746–52.
- 40. Gehrke N, Biedenbach J, Huber Y, Straub BK, Galle PR, Simon P, et al. Voluntary exercise
  in mice fed an obesogenic diet alters the hepatic immune phenotype and improves
  metabolic parameters an animal model of life style intervention in NAFLD. Sci Rep. 2019
  Mar 8;9(1):4007.
- 41. Gauthier MS, Couturier K, Charbonneau A, Lavoie JM. Effects of introducing physical
  training in the course of a 16-week high-fat diet regimen on hepatic steatosis, adipose tissue
  fat accumulation, and plasma lipid profile. Int J Obes. 2004 Aug;28(8):1064–71.
- 42. Linden MA, Fletcher JA, Morris EM, Meers GM, Laughlin MH, Booth FW, et al. Treating
   NAFLD in OLETF Rats with Vigorous-Intensity Interval Exercise Training. Med Sci Sports
   Exerc. 2015 Mar;47(3):556–67.
- 43. Sheldon RD, Laughlin MH, Rector RS. Reduced hepatic eNOS phosphorylation is
  associated with NAFLD and type 2 diabetes progression and is prevented by daily exercise
  in hyperphagic OLETF rats. J Appl Physiol. 2014 May 1;116(9):1156–64.
- 44. Balducci S, Cardelli P, Pugliese L, D'Errico V, Haxhi J, Alessi E, et al. Volume-dependent
  effect of supervised exercise training on fatty liver and visceral adiposity index in subjects
  with type 2 diabetes The Italian Diabetes Exercise Study (IDES). Diabetes Res Clin Pract.
  2015 Aug;109(2):355–63.
- 45. Shojaee-Moradie F, Cuthbertson DJ, Barrett M, Jackson NC, Herring R, Thomas EL, et al.
  Exercise Training Reduces Liver Fat and Increases Rates of VLDL Clearance But Not VLDL
  Production in NAFLD. J Clin Endocrinol Metab. 2016 Nov;101(11):4219–28.
- 46. Hallsworth K, Thoma C, Hollingsworth KG, Cassidy S, Anstee QM, Day CP, et al. Modified
  high-intensity interval training reduces liver fat and improves cardiac function in nonalcoholic fatty liver disease: a randomized controlled trial. Clin Sci. 2015 Dec
  1;129(12):1097–105.
- 47. Haufe S, Hupa-Breier KL, Bayerle P, Boeck HT, Rolff S, Sundermeier T, et al.
  Telemonitoring-Supported Exercise Training in Employees With Metabolic Syndrome
  Improves Liver Inflammation and Fibrosis. Clin Transl Gastroenterol. 2021
  Jun;12(6):e00371.
- 48. Rector RS, Uptergrove GM, Morris EM, Borengasser SJ, Laughlin MH, Booth FW, et al.
  Daily exercise vs. caloric restriction for prevention of nonalcoholic fatty liver disease in the
  OLETF rat model. Am J Physiol-Gastrointest Liver Physiol. 2011 May;300(5):G874–83.
- 49. Moore SC, Lee IM, Weiderpass E, Campbell PT, Sampson JN, Kitahara CM, et al.
  Association of Leisure-Time Physical Activity With Risk of 26 Types of Cancer in 1.44 Million
  Adults. JAMA Intern Med. 2016 Jun 1;176(6):816.
- 631 50. Rector RS, Thyfault JP, Morris RT, Laye MJ, Borengasser SJ, Booth FW, et al. Daily
  632 exercise increases hepatic fatty acid oxidation and prevents steatosis in Otsuka Long-Evans
  633 Tokushima Fatty rats. Am J Physiol-Gastrointest Liver Physiol. 2008 Mar;294(3):G619–26.


- 51. Fletcher JA, Meers GM, Laughlin MH, Ibdah JA, Thyfault JP, Rector RS. Modulating
  fibroblast growth factor 21 in hyperphagic OLETF rats with daily exercise and caloric
  restriction. Appl Physiol Nutr Metab. 2012 Dec;37(6):1054–62.
- 52. Borengasser SJ, Rector RS, Uptergrove GM, Morris EM, Perfield JW, Booth FW, et al.
  Exercise and Omega-3 Polyunsaturated Fatty Acid Supplementation for the Treatment of
  Hepatic Steatosis in Hyperphagic OLETF Rats. J Nutr Metab. 2012;2012:1–12.
- 53. Cho J, Kim S, Lee S, Kang H. Effect of Training Intensity on Nonalcoholic Fatty Liver
   Disease. Med Sci Sports Exerc. 2015 Aug;47(8):1624–34.
- 54. Cho J, Koh Y, Han J, Kim D, Kim T, Kang H. Adiponectin mediates the additive effects of
  combining daily exercise with caloric restriction for treatment of non-alcoholic fatty liver. Int J
  Obes. 2016 Nov;40(11):1760–7.
- 55. Dallak MA, Bin-Jaliah I, Albawardi A, Haidara MA, Sakr HF, Eid RA, et al. Swim exercise
  training ameliorates hepatocyte ultrastructural alterations in rats fed on a high fat and sugar
  diet. Ultrastruct Pathol. 2018 Mar 4;42(2):155–61.
- 648 56. Ghareghani P, Shanaki M, Ahmadi S, Khoshdel AR, Rezvan N, Meshkani R, et al. Aerobic
  649 endurance training improves nonalcoholic fatty liver disease (NAFLD) features via miR-33
  650 dependent autophagy induction in high fat diet fed mice. Obes Res Clin Pract. 2018
  651 Jan;12(1):80–9.
- 652 57. Gonçalves IO, Maciel E, Passos E, Torrella JR, Rizo D, Viscor G, et al. Exercise alters liver
  653 mitochondria phospholipidomic profile and mitochondrial activity in non-alcoholic
  654 steatohepatitis. Int J Biochem Cell Biol. 2014 Sep;54:163–73.
- 655 58. Gonçalves IO, Passos E, Diogo CV, Rocha-Rodrigues S, Santos-Alves E, Oliveira PJ, et al.
  656 Exercise mitigates mitochondrial permeability transition pore and quality control
  657 mechanisms alterations in nonalcoholic steatohepatitis. Appl Physiol Nutr Metab. 2016
  658 Mar;41(3):298–306.
- 659 59. Gonçalves IO, Passos E, Rocha-Rodrigues S, Torrella JR, Rizo D, Santos-Alves E, et al.
  660 Physical exercise antagonizes clinical and anatomical features characterizing Lieber661 DeCarli diet-induced obesity and related metabolic disorders. Clin Nutr. 2015
  662 Apr;34(2):241–7.
- 60. Guarino M, Kumar P, Felser A, Terracciano LM, Guixé-Muntet S, Humar B, et al. Exercise
  Attenuates the Transition from Fatty Liver to Steatohepatitis and Reduces Tumor Formation
  in Mice. Cancers. 2020 May 29;12(6):1407.
- 666 61. Kristensen CM, Dethlefsen MM, Tøndering AS, Lassen SB, Meldgaard JN, Ringholm S, et
  667 al. PGC-1 *α* in hepatic UPR during high-fat high-fructose diet and exercise training in mice.
  668 Physiol Rep. 2018 Aug;6(15):e13819.
- 669 62. La Fuente FP de, Quezada L, Sepúlveda C, Monsalves-Alvarez M, Rodríguez JM, Sacristán
   670 C, et al. Exercise regulates lipid droplet dynamics in normal and fatty liver. Biochim Biophys
   671 Acta BBA Mol Cell Biol Lipids. 2019 Dec;1864(12):158519.

- 63. Linden MA, Fletcher JA, Morris EM, Meers GM, Kearney ML, Crissey JM, et al. Combining
  metformin and aerobic exercise training in the treatment of type 2 diabetes and NAFLD in
  OLETF rats. Am J Physiol-Endocrinol Metab. 2014 Feb 1;306(3):E300–10.
- 675 64. Linden MA, Sheldon RD, Meers GM, Ortinau LC, Morris EM, Booth FW, et al. Aerobic
  676 exercise training in the treatment of non-alcoholic fatty liver disease related fibrosis: Treating
  677 western diet-induced NASH with exercise. J Physiol. 2016 Sep 15;594(18):5271–84.
- 678 65. Ok DP, Ko K, Bae JY. Exercise without dietary changes alleviates nonalcoholic fatty liver 679 disease without weight loss benefits. Lipids Health Dis. 2018 Dec;17(1):207.
- 66. Sakr HF, Abbas AM, Haidara MA. Swimming, but not vitamin E, ameliorates prothrombotic
  state and hypofibrinolysis in a rat model of nonalcoholic fatty liver disease. J Basic Clin
  Physiol Pharmacol. 2018 Jan 26;29(1):61–71.
- 67. Simko V, Kelley RE, Dincsoy HP, Gimmon Z, Willmann K. Exercise in rats with liver injury
  induced by carbon tetrachloride or bile duct obstruction. Blood cholic acid and liver
  histology. Res Exp Med (Berl). 1982 Jun;181(2):135–45.
- 686 68. Tang H, Tan X, Zhu L, Qin K, Gao H, Bai H. Swimming prevents nonalcoholic fatty liver
  687 disease by reducing migration inhibitory factor through Akt suppression and autophagy
  688 activation. Am J Transl Res. 2019;11(7):4315–25.
- 689 69. Xia SF, Jiang YY, Qiu YY, Huang W, Wang J. Role of diets and exercise in ameliorating
  690 obesity-related hepatic steatosis: Insights at the microRNA-dependent thyroid hormone
  691 synthesis and action. Life Sci. 2020 Feb;242:117182.
- 692 70. Sato Y, Qiu J, Miura T, Kohzuki M, Ito O. Effects of Long-Term Exercise on Liver Cyst in
   693 Polycystic Liver Disease Model Rats. Med Sci Sports Exerc. 2020 Jun;52(6):1272–9.




Identification of new studies via databases and registers

# Meta-analysis of human studies



# Meta-analysis of animal studies



-6

-4

-2

Study	Location	Design	Animal type (description), mean age	Liver disease, inducement method and inducement duration	Exercise groups	Comparison groups
Borengasser 2010	USA	Parallel RCT	Rats (OLETF male rats). 13- weeks old.	Hepatic steatosis, Genetic phenotype	Standard diet. Voluntary wheel running. N = 8. 7-weeks. Standard diet and fish oil. Voluntary wheel running. N = 8. 7-weeks.	Standard diet. N = 8. 8-weeks. Standard diet and fish oil. N = 8. 8-weeks.
Cho 2015	Korea	Parallel RCT	Mouse (Male C57BL/6). 4- weeks old.	NAFLD, diet induced over 8- weeks	High fat diet and vigorous exercise. $N = 10.8$ -weeks. High fat diet and moderate exercise. $N = 10.8$ -weeks.	Control diet. N = 6-7. 16-weeks. High fat diet. N = 30. 8-weeks.
Cho 2016	Republic of Korea	Parallel RCT	Mice (C57BL/6 male mice), 4 weeks old	NAFLD, diet induced over 16- weeks	High fat diet and continuous exercise. $N = 10.8$ -weeks. High fat diet then standard diet and exercise. $N = 10.8$ -weeks.	Standard diet. $N = 10.24$ -weeks. High fat diet. $N = 10.24$ -weeks. High fat diet to standard diet. $N = 10.24$ weeks (HFD) + 8-weeks (standard).
Dallak 2018	Saudi Arabia	Parallel RCT	Rats (Sprague Dawley. Sex not indicated). Unreported age.	NAFLD, diet induced over 15- weeks	Standard diet. Swimming exercise. N = 6. 15-weeks (4- weeks exercise). High cholesterol and fructose diet. Swimming exercise. N = 6. 15- weeks (4-weeks exercise).	Standard diet. N = 6. 15-weeks. High cholesterol and fructose diet. N = 6. 15-weeks.
Fletcher 2012	USA	Parallel RCT	Rats (OLETF males). 4- weeks old.	NAFLD, genetic phenotype.	OLETF rats. Voluntary exercise. N = 8. 36-weeks.	LETO rats. Standard diet. Sedentary. N = 8. 36-weeks. OLETF rats. Standard diet. Sedentary. N = 7. 36-weeks.
Gauthier 2004	Canada	Parallel RCT	Rats (Sprague- Dawley female). 6- weeks old.	Hepatic steatosis, diet induced over 8- weels	High fat diet and continuous exercise. N = 9 (from arm 2). 8- weeks.	Control diet, sedentary. N = 9. 16- weeks. High fat diet. Sedentary. N = 18. 8-weeks.
Gehrke 2019	Germany	Parallel RCT	Mice (C57BL/6J male mice). 8- 10 weeks old.	NAFLD, diet induced over 8- weeks.	Control diet and plain water. Voluntary exercise. N = 11. 12- weeks. High fat diet and enriched water. Voluntary exercise N = 11. 12- weeks.	Control diet and plain water. Sedentary. $N = 11$ . 12-weeks. High fat diet and enriched water. N = 11. 12-weeks.
Gharenghani	Iran	Parallel RCT	Mice (C57	NAFLD, diet	High fat diet and continuous	Standard diet. N = 8. 10 or 23

2018			male mice), age not reported.	induced over 13- weeks	exercise. N = 8. 10-weeks of exercise.	weeks. High fat diet. N = 8. 10 or 23 weeks.
Goncalves 2014	Portugal	Parallel RCT	Rats (Sprague- Dawley males). 5-6 weeks old.	NASH, diet induced over 17- weeks	Standard diet. Voluntary physical activity. N = 6. 17-weeks. Standard diet. Continuous exercise. N = 6. 8-weeks. High fat diet. Voluntary physical activity. N = 6. 17-weeks. High fat diet. Continuous exercise. N = 6. 8-weeks.	Standard diet. Sedentary. N = 6. 17-weeks. High fat diet. Sedentary. N = 6. 8- weeks.
Gonclaves 2014b	Portugal	Parallel RCT	Rats (Sprague- Dawley). 5-6 weeks old.	NASH, diet induced over 17- weeks	Standard diet. Voluntary exercise. N = 6. 17-weeks. Standard diet. Continuous exercise. N = 6. 17-weeks. High fat diet. Voluntary physical activity. N = 6. 17-weeks. High fat diet. Continuous exercise. N = 6. 8-weeks.	Standard diet. Sedentary. N = 6. 17-weeks. High fat diet. Sedentary.
Gonclaves 2015	Portugal	Parallel RCT	Rats (Sprague- Dawley). 5-6 weeks old.	NASH, diet induced over 17- weeks	Standard diet. Voluntary exercise. N = 10. 17-weeks. Standard diet. Continuous exercise. N = 10. 17-weeks. High fat diet. Exercise training. N = 10 (half of arm 2). 8-weeks of exercise.	Standard diet. Sedentary. N = 20. 17-weeks. High fat diet. Sedentary. N = 20. 17-weeks.
Gonclaves 2016	Portugal	Parallel RCT	Rats (Male Sprague Dawley). 5-6 weeks old.	NASH, diet induced over 17- weeks	Standard diet. Voluntary physical activity. Unclear N. 17-weeks. Standard diet. Continuous exercise. Unclear N. 8-weeks. High fat diet. Voluntary physical activity. Unclear N. 17-weeks. High fat diet. Continuous exercise. Unclear N. 8-weeks.	Sedentary. Unclear N. 17-weeks. High fat diet. Unclear N. 8-weeks.
Guarino 2020	Switzerland	Parallel RCT	Mice (C57Bl/6N male mice). 9- weeks old.	NAFLD, diet induced over 12- 20-weeks	Choline deficient high fat diet. Continuous exercise. N = 11. 8- weeks.	Standard diet. Sedentary. N = 11. 12-weeks. Choline deficient high fat diet. N = 11. 12-weeks.
Kristensen 2018	Denmark	Parallel RCT	Mouse (Liver- specific PGC- 1a knockout (LKO), Floxed mice, Cre	Hepatic steatosis, diet induced over 14- weeks	Floxed mice. High fat diet. Continuous exercise. N = 9-10. 9 weeks diet, 5-weeks exercise. Knockout mice. High fat diet. Continuous exercise. N = 9-10. 9	Floxed mice. Control diet. N = 9- 10. 14-weeks. Control diet. Knockout mice. N = 9-10. 14-weeks.

			mice). 8-9 weeks.		weeks diet, 5-weeks exercise.	
La Fuente 2019	South America	Parallel RCT	Mice (Male C57/BL6). 4- weeks old.	NAFLD, diet induced over 20- weeks	Standard diet. Continuous exercise. N = 9. 20-weeks. High fat diet. Continuous exercise. N = 9. 20-weeks.	Control diet. Sedentary. N = 6. 20-weeks. High fat diet. Sedentary. N = 9. 20-weeks.
Linden 2014	USA	Parallel RCT	Rats (Type 2 diabetic OLETF male rats/ Long- Evans Tokushima Otsuka (LETO) rats as controls). 20-weeks old.	NAFLD, sedentary OLETF rats develop NAFLD and hyperinsulinemia.	OLTEF rats. Continuous exercise. N = 10. 12-weeks.	LETO rats. Sedentary. N =10. 12- weeks. OLTEF rats. Sedentary. N = 10. 12-weeks.
Linden 2015	USA	Parallel RCT	Rats (OLETF male rats). 20- weeks old.	NASH, diet induced over 20- weeks	OLETF- rats. Moderate exercise. N = 8-10. 12-weeks. OLETF- rats. Vigorous exercise. N = 8-10. 12-weeks.	OLETF-sedentary rats. N = 8-10. 12-weeks. High fat diet. N = 8-10. 12-weeks.
Linden 2016	USA	Parallel RCT	Rats (Otsuka Long-Evans Tokushima Fatty (OLETF) and LETF (control) male rats). 8 or 20 weeks old.	Liver Fibrosis, diet induced over 12-weeks	Continuous moderate intensity exercise. N = 10. 12-weeks.	Sedentary. N = 12. 12-weeks. Food restriction. N = 9. 12-weeks.
Marques 2010	Brazil	Parallel RCT	Mice (C57BL/6 male mice). 3- months old.	NAFLD, diet induced over 8- weeks	Standard diet. Continuous exercise. N = 6. 8-weeks. High fat diet. Exercise. N = 6. 8- weeks.	Standard diet. N = 6. 8-weeks. High fat diet. N = 6. 8-weeks.
Ok 2018	Korea	Parallel RCT	Mice (Male C57/BL6). 8- weeks old.	NAFLD, diet induced over 24- weeks	High fat diet. Continuous exercise. $N = 8.24$ -weeks (8- weeks of exercise). High fat diet to normal diet and continuous exercise. $N = 8.24$ - weeks (8-weeks of exercise).	Control diet. Sedentary. N = 8. 24-weeks.
Rector 2008	USA	Parallel RCT	Rats (OLETF male rats). 4- weeks old.	NAFLD, OLETF rats develop hepatic steatosis and mild inflammation	OLTEF rats. Continuous exercise. N = 6-8. 16-weeks.	OLETF. Sedentary. N = 6-8. 16- weeks.

				comparable to NAFLD		
Rector 2011	USA	Parallel RCT	Rats (OLETF rats and LETO male rats). 4- weeks old.	NAFLD, OLETF rats develop hepatic steatosis and mild inflammation comparable to NAFLD	OLTEF rats. Voluntary exercise. N = 7-8. 36-weeks.	LETO. Sedentary. N = 7-8. 36- weeks. OLTEF. Sedentary. N = 7-8. 36- weeks. OLTEF rats and caloric restriction. N = 7-8. 36-weeks.
Sakr 2018	Egypt	Parallel RCT	Rats (Sprague- Dawley male mice). Unreported age.	NAFLD, diet induced over 15- weeks	Standard diet. Swimming exercise. N = 10. 15-weeks. Standard diet + vitamin E. Swimming. N = 10. 15-weeks. High fat diet. Swimming. N = 10. 15-weeks.	Standard diet. N = 6. 15-weeks. Standard diet + vitamin E. N = 10. 15-weeks. High fat diet. N = 10. 15-weeks.
Sato (Yoichi) 2020	Japan	Parallel RCT	Rats (PCK and Sprague- Dawley males). 5- weeks old.	Polycystic liver disease, Mutant rats with disease	PCK rats. Continuous exercise. N = 10. 12-weeks.	Sprague-Dawley rats. Sedentary. N = 10. 12-weeks. PCK rats. N = 10. 12-weeks.
Schultz 2012	Brazil	Parallel RCT	Mice (C57BL/6 male mice). 12-weeks old.	NAFLD, diet induced over 10- weeks	Standard diet. Swimming. $N = 10$ . 12 weeks + 10-weeks. High fat diet. Swimming. $N = 5$ . 12+10 weeks.	Standard diet. Sedentary. $N = 10$ . 12 weeks + 10-weeks. High fat diet. Sedentary. $N = 5$ . 12+10 weeks.
Silva 2014	Brazil	Parallel RCT	Rats (male Wistar). Unclear age.	NAFLD, diet induced over 12- weeks	Control diet and swimming. N = 6- 7. 4-weeks of swimming. High fat diet and swimming. N = 6-8/ 4-weeks of swimming.	Control diet. N = 6-7. 16-weeks. High fat diet. N = 6-7. 16-weeks.
Simko 1982	USA	Parallel RCT	Rats (Male Sprague Dawley). Unclear age.	Treatment with carbon tetrachloride or extrahepatic obstruction, Drug induced over 20- days.	CCL4 treatment. Swimming. N = 8. 20-days. Tied bile duct. Swimming. N = 10. Unclear timing.	Sedentary. N = 9. 20-days. CCL4 treatment. Sedentary. N = 7. 20-days.
Tang 2019	China	Parallel RCT	Mice (C57/BL6 wild type and migration inhibitory factor KO male mice). 6-	NAFLD, diet induced over 10- weeks	Wild type mice. High fat diet. Swimming. N = 5. 10+10-weeks. Migration inhibitory factor knock out mice. High fat diet. Exercise. N = 5. 10+10-weeks.	Wild type mice. High fat diet. Sedentary. $N = 5$ . 10+10-weeks. Migration inhibitory factor knock out mice. High fat diet. $N = 5$ . 10+10-weeks.

			weeks old.			
Xia 2020	China	Parallel RCT	Mice (Sprague- Dawley). 4- weeks.	Hepatic steatosis, diet induced over 10- weeks	Obesity prone mice (from high fat diet). Continuous exercise. N = 8. 7-weeks.	Low fat diet. Sedentary. N = 8. 17-weeks. High fat diet. Sedentary. N = 80 (initially). 10-weeks. Obesity prone mice (as above). Maintained diet and sedentary status. N = 8. 7-weeks.

Study	Location	Randomised design	Diagnosis	Sample N	Female (%)	Follow-up duration (weeks)	Intervention: comparison N	Intervention arm(s) description	Comparison arm(s) description
Abdelbasset 2020	Egypt	Controlled	NAFLD	48	43	8	32:16	a) MICT b) HIIT	Control
Balducci 2015	Italy	Controlled	T2DM	606	42	52	303:303	a) Low-MICT + RT b) Mod-HICT + RT	Standard care
Cheng 2017	China	Controlled	NAFLD	115	77	34	58:57	a) MICT b) MICT + diet	a) No intervention b) Diet
Hallsworth 2011	UK	Controlled	NAFLD	19	NR	8	11:8	RT	Control
Hallsworth 2015	UK	Controlled	NAFLD	29	NR	12	15:14	ніт	Standard care
Haufe 2021	Germany	Controlled	MetS	314	14	26	160:154	МІСТ	Wait-list control
Houghton 2017	UK	Controlled	NASH	24	NR	12	12::12	MICT + RT	Standard care
Kelardeh 2020	Iran	Placebo	NAFLD	45	100	12	23:22	a) RT b) RT + curcumin	a) Curcumin placebo b) Curcumin
Pugh 2013	UK	Controlled	NAFLD	13	54	16	6:5	МІСТ	Standard care
Pugh 2014	UK		NAFLD	21	48	16	18:13	МІСТ	Diet and PA advice
Rezende 2016	Brazil	Controlled	NAFLD	44	100	24	21:23	МІСТ	Control
Sirisunhirun 2022	Thailand		Liver Cirrhosis	40	35	12	20:20	MICT + RT	PA advice & self- monitoring
St George 2009	Australia	Controlled	NAFLD	141	38	13	107:34	a) MICT + 3 CS b) MICT + 6 CS c) MICT + 6 CS + TS	Control
Sullivan 2012	USA	Controlled	NAFLD	18	72	16	12:6	МІСТ	Control
Takahashi 2015	Japan		NAFLD	53	64	12	31:22	RT	Diet and PA advice
Tutino 2018	Italy	Comparative	NAFLD	142	40	13	101:41	a) MICT b) MICT + RT	a) Control diet b) LGIMD

								c) MICT + LGIMD d) MICT + RT + LGIMD	
Zelber-Sagi 2014	Israel	Placebo	NAFLD	82	47	12	44:38	RT	Stretching
Zhang 2016	China	Controlled	NAFLD	220	68	48	146:74	VICT + MICT	Control